Annexon, Inc. (ANNX) Stock

Annexon, Inc. (ANNX) is a Healthcare stock trading at $4.91 (as of 2026-06-18), with a market capitalization of $1.05B and a trailing P/E of -3.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. Its pipeline includes monoclonal antibodies such as ANX005 and ANX009 and other candidates, including ANX007, ANX105, and the oral small molecule ANX1502, which are being evaluated in clinical trials for conditions including Guillain-Barré syndrome and lupus nephritis.

Valuation — source: SEC EDGAR (first-party)
Price	$4.91
Market Cap	$1.05B
P/E Ratio	-3.9
EV / EBITDA	-3.6
Price / Book	4.47
DCF Value (model)	$-20.16
DCF Upside vs Price	-511.0%

Profitability & Growth — source: SEC EDGAR
Return on Equity	-96.1%
Current Ratio	6.35

Valuation vs Sector & Industry
Stock P/E	-3.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-118.8%
vs Industry	-123.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Redmile Group, LLC ($80.61M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Douglas E. Love
Employees	106
Country	US
IPO Date	2020-07-24

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.